James Perry, DO
Critical Care Medicine · South Charleston, WVNPI 1679893036
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,139 of the $11,889 with a category attached, or 68.5%. 34 manufacturers reported payments, led by Intuitive Surgical at 30.7% of the total. Reporting peaked in 2023 at $5,173 and has fallen 80.1% since, to $1,029 in 2025.
Across 459 payments — averaging $25.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$841
- Boehringer Ingelheim$748
- Novartis$732
- plus $3K from 28 others
What the payments were for
- Travel & lodging$5124%
- Food & beverage$8,13968%
- Education$3,23827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $3,645 |
| GSK | 95 | $1,290 |
| AstraZeneca(2 entities) | 62 | $1,147 |
| Regeneron Healthcare Solutions, Inc. | 34 | $841 |
| Boehringer Ingelheim | 42 | $748 |
| Novartis | 40 | $732 |
| Sanofi | 31 | $694 |
| Insmed, Inc. | 20 | $360 |
| Axsome Therapeutics, Inc. | 11 | $261 |
| Actelion Pharmaceuticals US, Inc. | 3 | $238 |
| Pulmonx Corporation | 9 | $221 |
| Jazz Pharmaceuticals Inc. | 10 | $172 |
| Mylan Specialty L.p. | 9 | $155 |
| Sunovion Pharmaceuticals Inc. | 12 | $151 |
| Genentech USA, Inc. | 10 | $148 |
| Verona Pharma, Inc. | 9 | $139 |
| Merck | 9 | $129 |
| Amgen | 7 | $126 |
| Grifols USA, LLC | 6 | $125 |
| Electromed, Inc. | 11 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $87 |
| Pfizer | 4 | $68 |
| United Therapeutics Corporation | 3 | $64 |
| La Jolla Pharmaceutical Company | 3 | $47 |
| Philips North America LLC | 1 | $34 |
| Galvanize Therapeutics, Inc | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Harmony Biosciences LLC | 1 | $23 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Ambu Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$474
- FASENRA$125
- BREZTRI$125
How this compares
$11,889 in reported general payments places this provider in the 85th percentile of 29 critical care medicine providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 50 | $654,725 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 31 | $415,088 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 361 | $359,375 |
| OpsumitMacitentan | 13 | $164,161 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $145,936 |
| XolairOmalizumab | 36 | $141,705 |
| Dupixent SyringeDupilumab | 30 | $117,094 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 109 | $98,420 |
| NucalaMepolizumab | 16 | $88,752 |
| Dupixent PenDupilumab | 19 | $74,771 |
| Spiriva RespimatTiotropium Bromide | 70 | $57,025 |
| SymbicortBudesonide/Formoterol Fumarate | 122 | $48,667 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $35,814 |
| Incruse ElliptaUmeclidinium Bromide | 73 | $34,770 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $34,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $748 | $736,860169 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $1,290 | $559,302581 claims |
| Grifols USA, LLCProlastin C | $125 | $415,08831 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $238 | $164,16113 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,147 | $147,086231 claims |
| PfizerEliquis | $68 | $24,12338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 29 critical care medicine providers in West Virginia.
Other critical care medicine in South Charleston
- Phillip CoxSouth Charleston$20K
- Kevin EgglestonSouth Charleston$13K
- Robby KeithSouth Charleston$12K
- Tamejiro TakuboSouth Charleston$10K
- William WadeSouth Charleston$7K
- Parag ChaudhariMorgantown$8K
- William BeamHuntington$2K
- Brownhilda SantoParkersburg$2K
- Zan ShareefCharleston$2K
- Kaitlin McDadeCharleston$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.